China National Pharmaceutical Group: Wholly-owned subsidiary's application for market approval of raw materials for minaprine hydrochloride approved.

China National Pharmaceutical Group Corporation (Sinopharm) announced that its wholly-owned subsidiary, Jiangsu Weichida, has received the "Chemical API Market Application Approval Letter" issued by the National Medical Products Administration for the active pharmaceutical ingredient Mirtazapine hydrochloride. Mirtazapine hydrochloride is used to treat severe depression, with a global consumption of 3,639.95 kg in 2023. Jiangsu Weichida submitted the application in October 2024, passed the review in February 2026, with a total research and development investment of approximately 7.1823 million yuan. The approval of this active pharmaceutical ingredient will help the company advance its industrial chain integration, but sales may be affected by multiple factors, leading to uncertainties.